Revogenex, Inc. Report issue

For profit Phase 2
Founded: Duluth GA United States (2009)
Status: Acquired by Fortress Biotech (2015)

Organization Overview

First Clinical Trial
2010
NCT01076699
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

rvx-100 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diarrhea (Phase 2)

Irritable Bowel Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1